Questions About Cancer? 1-800-4-CANCER
NCI Cancer Center News

UAB study finds PARP inhibitors may have clinical utility in HER2-positive breast cancers

  • Posted: September 17, 2012

Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive breast cancers, according to the results of a University of Alabama-Birmingham study published in Cancer Research, a journal of the American Association for Cancer Research. The University of Alabama-Birmingham is home to the UAB Comprehensive Cancer Center.

Click here to read the full release.


NCI comprehensive cancer centers logoAmong the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.